Purchase this article with an account.
Manju N. Chandran, Jr., Lorraine North, Subhasree Dhananjayan, Jr., Leena Jain, Jr., Gulrez Ansari, Jr., Narendran Nair, Jr., Sidharth Praveen, Jr., Geeta Menon, IV; Association of photoreceptor integrity and visual outcome in Retinal Vein Occlusion (RVO) treated with intravitreal Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2012;53(14):827. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the significance of photoreceptor layer status, and external limiting membrane using Spectral Domain Optical CoherenceTomography(SD-OCT), as a prognostic indicator in eyes with macular oedema secondary to retinal vein occlusion (RVO) treated with intravitreal Bevacizumab.
Retrospective analysis of 24 eyes of 24 patients who had macular oedema secondary to RVO was carried out. Treatment consisted of three consecutive monthly injections of intravitreal Bevacizumab 1.25mg/0.05ml, followed by retreatment based on OCT findings. Using SD -OCT the status of inner segment and outer segment (IS/OS) photoreceptor junction was assessed as a marker of integrity of photoreceptor layer along with the status of the external limiting membrane (ELM). These findings were correlated with visual acuity (VA) outcome.
Mean VA was 51.27 letters at baseline and showed a statistically significant improvement of 11.08 letters at 12months(p<0.01 ). Baseline CMT was 426.16 microns and showed a reduction of 287.6 microns at 12 months(p<0.01). Intact ELM and IS/OS lines was found in 95.8% of cases who had a positive visual outcome(p<.01). 4.2% had loss of more than 15 letters and this was associated with disrupted ELM and IS/OS lines. Patients received a mean of 7.3 injections during the 12month follow up period. No systemic or ocular adverse events were reported.
Integrity of the photoreceptor layer beneath the fovea showed a statistically significant correlation with positive visual acuity outcome in macular oedema secondary to RVO treated with intravitreal Bevacizumab.
This PDF is available to Subscribers Only